Kidney Cancer Drugs Market By Therapy Class (Targeted Therapy, Immunotherapy, and Chemotherapy), By Pharmacologic Class (Angiogenesis Inhibitors, mTOR Inhibitors, Cytokines, Others (Immune Checkpoint Inhibitors, CTLA-4 inhibitors, and Antimetabolites)), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and By Region - Trends, Analysis and Forecast till 2030

Kidney cancer is most common type of cancer in which cancerous cells grow inside the tissues of kidney which affects functioning of the normal cells. Kidney cancer can be caused due to risk factors such as smoking, obesity; inhalation of herbicides, and organic solvents based chemicals, high blood pressure as well as genetic and hereditary factors.

Increasing prevalence of kidney cancer, owing to increasing obesity among the individuals across the globe is a major factor driving growth of the kidney cancer drugs market. In addition, increasing government funding for the research and development of new drugs is expected to propel growth of the target market in the near future. However, lack of awareness about availability of kidney cancer drugs among the individuals is a key factor restraining growth of the kidney cancer drugs market.

The kidney cancer drugs market has been segmented on the basis of therapy class, pharmacologic class, distribution channel, and region.

The therapy class segment includes targeted therapy, immunotherapy and chemotherapy. On the basis of pharmacological class segment the target market has been segmented as angiogenesis inhibitors, mTOR inhibitors, cytokines, and others. Others pharmacological class is further sub-segmented into immune checkpoint inhibitors, ctla-4 inhibitors, and antimetabolites.

On the basis of distribution channel the kidney cancer drugs market has been segmented as hospital, retail pharmacy, and online pharmacy.

Regional Insights:

On the basis of region the target market has been segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is expected to account major market share as compared to that of other regions. This can be attributed to rapid growth in the ratio of kidney cancer disease, advancements in the novel cancer therapies, and well established health care sector in the countries of the region.

Key players operating in the kidney cancer drugs market includes Pfizer Inc., Novartis International AG, Genentech Inc., Active Biotech AB, Amgen Inc., Bayer AG, Cipla Limited, Hoffmann-La Roche AG, Eisai Co., Ltd. and Exelixis, Inc.